Last reviewed · How we verify
NCT03276286: NAT109
Nativis Voyager for Newly Diagnosed GBM
NA trial testing Nativis Voyager in Glioblastoma Multiforme in 37 participants. Completed in 31 May 2022.
31 May 2022
Quick facts
| Lead sponsor | Nativis, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | device feasibility |
| Enrollment | 37 |
| Start date | 10 November 2017 |
| Primary completion | 31 May 2022 |
| Estimated completion | 31 May 2022 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Nativis Voyager
Conditions studied
- Glioblastoma Multiforme — all drugs for Glioblastoma Multiforme →
Sponsor
Nativis, Inc.
Who can join
18 and older, any sex, with Glioblastoma Multiforme. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and temozolomide.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
An early feasibility study of the Nativis Voyager<sup>®</sup> device in patients with recurrent glioblastoma: first cohort in US.
Cobbs C, McClay E, Duic JP, Nabors LB, et al · · 2019 · cited 12× · PMID 30547676 · DOI 10.2217/cns-2018-0013 -
A feasibility study of the Nativis Voyager<sup>®</sup> device in patients with recurrent glioblastoma in Australia.
Murphy M, Dowling A, Thien C, Priest E, et al · · 2019 · cited 10× · PMID 30727742 · DOI 10.2217/cns-2018-0017
Verify or expand the search:
- PubMed search for NCT03276286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioblastoma Multiforme
Currently open trials in the same condition.
- NCT06466031 — Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO] · NA · recruiting
- NCT06333899 — Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · EARLY_PHASE1 · recruiting
- NCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age · Phase 1, PHASE2 · recruiting
- NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
- NCT06329570 — Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multif · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03276286 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nativis, Inc.
- Last refreshed: 2 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03276286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing